Table 2.
Participant characteristics. Participants excluded from the data analyses are not included.
| Characteristics | TRACK-HD | Enroll-HD | TRACK-HD and Enroll-HD |
|---|---|---|---|
| Number of individuals | 203 | 531 | 734 |
| Range of age at DNA sampling (years) | 18·63 to 64·13 | 18·42 to 75·50 | 18·42 to 75·50 |
| Mean age at DNA sampling (years (SD)) | 45·00 (9·93) | 48·84 (12·25) | 47·78 (11·77) |
| Range of age at baseline (years) | 18·63 to 64·13 | 18·42 to 75·50 | 18·42 to 75·50 |
| Mean age at baseline (years (SD)) | 44·96 (9·90) | 48·84 (12·25) | 47·77 (11·77) |
| Sex = female (%) | 54·68 | 53·67 | 53·95 |
| Manifest for Huntington disease motor symptoms | 48·28% | 73·45% | 66·49% |
| Mean age at onset of motor symptoms (years (SD)) | 45·27 (8·89) | 45·85 (10·72) | 45·73 (10·37) |
| Mean total motor score at baseline (SD) | 12·06 (12·64) | 23·58 (20·40) | 20·40 (19·27) |
| Mean total functional capacity at baseline (SD) | 11·93 (1·73) | NA | NA |
| Mean pure CAG (Q1) in the disease-associated allele (SD) | 43·14 (2·16) | 43·25 (2·40) | 43·22 (2·33) |
| Mean total encoded glutamine (QT) in the disease-associated allele (SD) | 45·18 (2·25) | 45·26 (2·42) | 45·24 (2·37) |
| Mean fragment length estimate of CAG (QFL) in the disease-associated allele (SD) | 43·15 (2·21) | 43·25 (2·42) | 43·22 (2·36) |